Pfizer Settles with Teva over Lipitor in U.K.

WALTON OAKS, U.K., October 7, 2011 - Pfizer Inc. announced today that the company has settled its patent-infringement case against Teva and several other parties in respect of Teva's generic form of Lipitor in the U.K. Under the terms of the settlement agreement Teva and the other settling parties agree not to sell Teva's atorvastatin product in the U.K. before patent expiry in May of 2012.  Teva acknowledges that Pfizer's Lipitor patent is valid and infringed by Teva's product. Other terms of the settlement remain confidential.

The settlement announced today is with Teva UK Limited, Phoenix Healthcare Distribution Limited, Barclay Pharmaceuticals Limited, AAH Pharmaceuticals Limited, L Rowland & Co (Retail) Ltd and Day Lewis PLC.

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.